Showing results (621-630 of 673) with videos related to

Sort By:
Pageof 68
NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
The New England Journal of Medicine|February 12, 2015
Effect of mutation order on myeloproliferative neoplasmsChristina A Ortmann, David G Kent, Jyoti Nangalia, et al.
Journal of Hospital Medicine|February 22, 2024
Differences in testing for drugs of abuse amongst racial and ethnic groups at children's hospitalsAdriana Herrera, Matt Hall, Marshall Alex Ahearn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 4, 2024
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY StudiesStacie Hudgens, Srdan Verstovsek, Lysbeth Floden, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Medical Education Online|February 22, 2023
Applying motivational framework in medical education: a self-determination theory perspectivesFraide A Ganotice, Karen M K Chan, Siu Ling Chan, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
Blood|November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosisPeter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.
Blood Advances|February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaHarinder Gill, Francesca Palandri, David M Ross, et al.
Pageof 68